Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Xiao Huang; Hai Lin; Feng Huang; Yuning Xie; Ka Hong Wong; Xiaoyu Chen; Dongyue Wu; Aiping Lu; Zhijun Yang

doi:10.1177/1559325819887048

Targeting Approaches of Nanomedicines in Acute Myeloid Leukemia

Dose Response. 2019 Dec 11;17(4):1559325819887048. doi: 10.1177/1559325819887048. eCollection 2019 Oct-Dec.

Authors

Xiao Huang¹, Hai Lin², Feng Huang³, Yuning Xie¹, Ka Hong Wong¹, Xiaoyu Chen¹, Dongyue Wu², Aiping Lu¹, Zhijun Yang¹

Affiliations

¹ School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
² Department of Traditional Chinese Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
³ Institute of Acupuncture & Moxibustion, China Academy of Chinese Medical Sciences, Beijing, China.

Abstract

Acute myeloid leukemia (AML) is a hematological malignancy, which is commonly associated with high incidence and mortality among adult patients. The standard induction regimen for AML has been substantially unchanged over the past 40 years, for which novel nanomedicines have represented a promising strategy in AML therapies. Despite developments of multiple nanoparticles formulated with drugs or genes, less there is not much information available about approaches in AML is available. This review presents an overview of nanomedicines currently being evaluated in AML. First, it briefly summarized conventional chemotherapies in use. Second, nanomedicines presently ongoing in clinical trials or preclinical researches were classified and described, with illustrative examples from recent literatures. Finally, limitations and potential safety issues concerns in clinical translation of AML treatment were discussed as well.

Keywords: acute myeloid leukemia; cancer therapy; nanomedicines; nanoparticles.

Publication types

Review